Published in Environ Health Perspect on June 01, 1976
Alterations in xenobiotic metabolism in the long-lived Little mice. Aging Cell (2007) 2.35
Overview of an interlaboratory collaboration on evaluating the effects of model hepatotoxicants on hepatic gene expression. Environ Health Perspect (2004) 1.30
Scanning electron microscopic examination of acetaminophen-induced hepatotoxicity and congestion in mice. Am J Pathol (1983) 1.03
Modeling Epoxidation of Drug-like Molecules with a Deep Machine Learning Network. ACS Cent Sci (2015) 0.84
Characterization of acute 4,4'-methylene dianiline hepatotoxicity in the rat. Environ Health Perspect (1993) 0.82
Effects of PBBs on cattle. III. Target organ modification as shown by renal function and liver biochemistry. Environ Health Perspect (1978) 0.81
S-adenosyl-l-methionine protection of acetaminophen mediated oxidative stress and identification of hepatic 4-hydroxynonenal protein adducts by mass spectrometry. Toxicol Appl Pharmacol (2014) 0.79
A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy. Antimicrob Agents Chemother (2016) 0.75
Carcinogenic nitroso compounds. Adv Cancer Res (1967) 6.01
Biochemical studies of toxic agents. 11. The occurrence of premercapturic acids. Biochem J (1958) 5.53
Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther (1973) 5.23
Carcinogenesis by chemicals: an overview--G. H. A. Clowes memorial lecture. Cancer Res (1970) 4.83
Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther (1973) 4.40
Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology (1974) 4.32
Carbon tetrachloride hepatotoxicity. Pharmacol Rev (1967) 3.77
Liver necrosis from paracetamol. Br J Pharmacol Chemother (1966) 3.77
Arene oxides: a new aspect of drug metabolism. Science (1974) 3.34
Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin Pharmacol Ther (1974) 2.62
Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med (1976) 2.33
Isoniazid-associated hepatitis in 114 patients. Gastroenterology (1975) 2.02
Possible mechanism of liver necrosis caused by aromatic organic compounds. Proc Natl Acad Sci U S A (1971) 2.00
Mechanisms of chemical carcinogenesis: nature of proximate carcinogens and interactions with macromolecules. Pharmacol Rev (1966) 1.98
Studies in detoxication. 51. The determination of catechols in urine, and the formation of catechols in rabbits receiving halogenobenzenes and other compounds; dihydroxylation in vivo. Biochem J (1953) 1.97
Acetaminophen-induced hepatic necrosis. 3. Cytochrome P-450-mediated covalent binding in vitro. J Pharmacol Exp Ther (1973) 1.90
Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther (1975) 1.75
Acetaminophen-induced hepatic necrosis. VI. Metabolic disposition of toxic and nontoxic doses of acetaminophen. Pharmacology (1974) 1.70
The effect of diet on the toxicity of paracetamol and the safety of paracetamol-methionine mixtures. Biochem Pharmacol (1975) 1.48
Acetaminophen-induced hepatic necrosis. V. Correlation of hepatic necrosis, covalent binding and glutathione depletion in hamsters. Pharmacology (1974) 1.43
Progress in hepatology. Metabolic activation of drugs to toxic substances. Gastroenterology (1975) 1.42
Centrolobular hepatic necrosis related to covalent binding of metabolites of halogenated aromatic hydrocarbons. Exp Mol Pathol (1973) 1.27
Metabolism and binding of aromatic hydrocarbons in the lung. Relationship to experimental bronchiolar necrosis. Am Rev Respir Dis (1973) 1.17
Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy. Chest (1975) 1.12
Species differences in hepatic glutathione depletion, covalent binding and hepatic necrosis after acetaminophen. Life Sci (1974) 1.02
Role of detoxifying enzymes in bromobenzene-induced liver necrosis. J Pharmacol Exp Ther (1973) 0.99
Relationship of alcohol metabolism to the potentiation of CCl 4 hepatotoxicity induced by aliphatic alcohols. J Pharmacol Exp Ther (1972) 0.97
Hepatic necrosis caused by furosemide. Nature (1974) 0.89
Drug metabolism as a cause of drug toxicity. Drug Metab Dispos (1974) 0.85
Relative contributions of history-taking, physical examination, and laboratory investigation to diagnosis and management of medical outpatients. Br Med J (1975) 9.18
Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther (1973) 5.23
Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther (1973) 4.40
Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology (1974) 4.32
A randomised trial of home-versus-hospital management for patients with suspected myocardial infarction. Lancet (1978) 4.12
Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp Ther (1973) 3.89
Interim discharge summaries: how are they best delivered to general practitioners? Br Med J (Clin Res Ed) (1987) 3.64
Menopausal flushing: does oestrogen therapy make sense? Lancet (1976) 3.47
Self-poisoning: management of patients in Nottingham, 1976. Br Med J (1978) 3.24
Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin Pharmacol Ther (1974) 2.62
Accumulation and elimination of poliovirus by the eastern oyster. Am J Epidemiol (1966) 2.58
Randomised placebo-controlled trial comparing oxprenolol with disopyramide phosphate in immediate treatment of suspected myocardial infarction. Lancet (1980) 2.53
Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med (1976) 2.33
Randomised trial comparing propranolol with atenolol in immediate treatment of suspected myocardial infarction. Br Med J (1980) 2.32
Guanethidine and related agents. 3. Antagonism by drugs which inhibit the norepinephrine pump in man. J Clin Invest (1970) 2.29
RNA binding domain of telomerase reverse transcriptase. Mol Cell Biol (2001) 2.27
Effect of a pyrimidopyrimidine derivative on thrombus formation in the rabbit. Nature (1965) 2.19
Is nursing any business of doctors? A simple guide to the "nursing process". Br Med J (Clin Res Ed) (1984) 2.17
Early reporting of myocardial infarction: impact of an experiment in patient education. Br Med J (Clin Res Ed) (1982) 2.11
Isoniazid-associated hepatitis in 114 patients. Gastroenterology (1975) 2.02
Possible mechanism of liver necrosis caused by aromatic organic compounds. Proc Natl Acad Sci U S A (1971) 2.00
Platelet reactivity and serum thromboxane B2 production in whole blood in gestational hypertension and pre-eclampsia. Br J Obstet Gynaecol (1991) 1.91
Acetaminophen-induced hepatic necrosis. 3. Cytochrome P-450-mediated covalent binding in vitro. J Pharmacol Exp Ther (1973) 1.90
Effect of prostaglandin E1 on platelet behaviour in vitro and in vivo. Br Med J (1967) 1.85
Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. Lancet (1985) 1.84
An association between abo blood-group distribution and geographical differences in death-rates. Lancet (1977) 1.81
Effect of dipyridamole on human platelet behaviour. Lancet (1965) 1.79
Plasma glutathione and glutathione disulfide in the rat: regulation and response to oxidative stress. J Pharmacol Exp Ther (1983) 1.79
Studies on the rate of reduction of hepatic microsomal cytochrome P-450 by reduced nicotinamide adenine dinucleotide phosphate: effect of drug substrates. Mol Pharmacol (1969) 1.76
Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther (1975) 1.75
Oxidation of alpha-methyldopa and other catechols by cytochrome P-450-generated superoxide anion: possible mechanism of methyldopa hepatitis. Mol Pharmacol (1976) 1.73
Dexamethasone in acute stroke. Br Med J (1978) 1.73
Prontosil in Erysipelas. Br Med J (1937) 1.70
Acetaminophen-induced hepatic necrosis. VI. Metabolic disposition of toxic and nontoxic doses of acetaminophen. Pharmacology (1974) 1.70
Comparative effects of p-chloroamphetamine and p-chloro-N-methylamphetamine on rat brain norepinephrine, serotonin and 5-hydroxyindole-3-acetic acid. Biochem Pharmacol (1970) 1.69
Biochemistry of drug oxidation and reduction by enzymes in hepatic endoplasmic reticulum. Adv Pharmacol (1966) 1.68
Is an information booklet for patients leaving hospital helpful and useful? BMJ (1989) 1.68
Antagonism of the antihypertensive action of guanethidine sulfate by desipramine hydrochloride. JAMA (1967) 1.67
What constitutes evidence on the dietary prevention of coronary heart disease? Cosy beliefs or harsh facts? Int J Cardiol (1984) 1.66
Changes in Michaelis and spectral constants for aniline in hepatic microsomes from phenobarbital-treated rats. Mol Pharmacol (1969) 1.62
Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet (1988) 1.62
The role of the interview in student selection. S Afr Med J (1978) 1.59
Autumn Books: Who needs Clinical Pharmacology? Br Med J (Clin Res Ed) (1984) 1.57
Sulphanilamide in the Treatment of Erysipelas. Br Med J (1937) 1.56
"But will it help my patients with myocardial infarction?" The implications of recent trials for everyday country folk. Br Med J (Clin Res Ed) (1982) 1.55
Effect of aggregating agents on the electrophoretic mobility of human platelets. Br Med J (1966) 1.55
Prevention and diagnosis of venous thrombosis in patients with hip fractures. A survey of current practice. Lancet (1976) 1.52
Blood pressure reduction in elderly: a randomised controlled trial of methyldopa. Br Med J (Clin Res Ed) (1981) 1.52
Effect of oestrogens on human platelet behaviour. Lancet (1968) 1.49
Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther (2009) 1.48
Low dose beta blockade in acute stroke ("BEST" trial): an evaluation. Br Med J (Clin Res Ed) (1988) 1.47
Use of isolated perfused organs in hypoxia and ischemia/reperfusion oxidant stress. Methods Enzymol (1990) 1.46
Patients' and general practitioners' satisfaction with information given on discharge from hospital: audit of a new information card. BMJ (1989) 1.45
Studies on the destruction of liver microsomal cytochrome P-450 by carbon tetrachloride administration. Biochem Pharmacol (1968) 1.43
Acetaminophen-induced hepatic necrosis. V. Correlation of hepatic necrosis, covalent binding and glutathione depletion in hamsters. Pharmacology (1974) 1.43
Progress in hepatology. Metabolic activation of drugs to toxic substances. Gastroenterology (1975) 1.42
Reactive oxygen species during ischemia-reflow injury in isolated perfused rat liver. J Clin Invest (1988) 1.38
Parent and peer attachment in early adolescent depression. J Abnorm Child Psychol (1990) 1.38
Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science (1976) 1.38
Magnetization transfer and multicomponent T2 relaxation measurements with histopathologic correlation in an experimental model of MS. J Magn Reson Imaging (2000) 1.37
Anticoagulants in coronary heart disease--retrospect and prospect. Lancet (1981) 1.36
Platelet behaviour and drugs used in cardiovascular disease. Cardiovasc Res (1967) 1.32
Abnormalities in platelet behaviour in acute illnesses. Br Med J (1966) 1.31
Treatment of high blood pressure: should clinical practice be based on results of clinical trials? Br Med J (Clin Res Ed) (1986) 1.31
Mechanism of action of N-acetylcysteine in the protection against the hepatotoxicity of acetaminophen in rats in vivo. J Clin Invest (1983) 1.31
Nature of the transferable factor which causes abnormal platelet behaviour in vascular disease. Lancet (1967) 1.27
Clinical management of venous thrombo-embolism. Br Med Bull (1978) 1.26
Contribution of atenolol, bendrofluazide, and hydrallazine to management of severe hypertension. Br Med J (1977) 1.26
Organisation of the external region of the starch granule as determined by infrared spectroscopy. Int J Biol Macromol (2002) 1.26
Guanethidine and related agents. I. Mechanism of the selective blockade of adrenergic neurons and its antagonism by drugs. J Pharmacol Exp Ther (1970) 1.26
Timolol after myocardial infarction: an answer or a new set of questions? Br Med J (Clin Res Ed) (1981) 1.25
Platelet aggregation in whole blood determined using the Ultra-Flo 100 Platelet Counter. Thromb Haemost (1982) 1.25
Pilot studies on recombinant cold-adapted live type A and B influenza virus vaccines. J Infect Dis (1977) 1.25
Effects of N-acetylcysteine on acetaminophen covalent binding and hepatic necrosis in mice. J Pharmacol Exp Ther (1985) 1.24
Hepatic glutathione homeostasis in the rat: efflux accounts for glutathione turnover. Hepatology (1984) 1.23
Effect of oral contraceptive agents on platelets and plasma-phospholipids. Lancet (1968) 1.23
Developments in understanding the basis of cooked-rice texture. Crit Rev Food Sci Nutr (2000) 1.23
Oestrogen treatment for menopausal flushing. Br Med J (1977) 1.21
Immunological studies on the mechanism of halothane-induced hepatotoxicity: immunohistochemical evidence of trifluoroacetylated hepatocytes. J Pharmacol Exp Ther (1985) 1.21
The effect of phenobarbital on the turnover of microsomal phospholipid in male and female rats. J Biol Chem (1968) 1.21
Species and sex differences in electron transport systems in liver microsomes and their relationship to ethylmorphine demethylation. Life Sci (1969) 1.20
Diverse effects of SKF 525-A and antioxidants on carbon tetrachloride-induced changes in liver microsomal P-450 content and ethylmorphine metabolism. Life Sci (1968) 1.19
The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult Scler (2007) 1.18
Biliary excretion of glutathione and glutathione disulfide in the rat. Regulation and response to oxidative stress. J Clin Invest (1984) 1.18
Impact of particle size distribution on rheological and textural properties of chocolate models with reduced fat content. J Food Sci (2007) 1.18
Molecular basis for several drug-induced nephropathies. Am J Med (1977) 1.18
Acute pulmonary injury in rats by nitrofurantoin and modification by vitamin E, dietary fat, and oxygen. Am Rev Respir Dis (1979) 1.18
Neonatal platelet reactivity and serum thromboxane B2 production in whole blood: the effect of maternal low dose aspirin. Br J Obstet Gynaecol (1994) 1.18
Evidence that acetaminophen and N-hydroxyacetaminophen form a common arylating intermediate, N-acetyl-p-benzoquinoneimine. Mol Pharmacol (1980) 1.18
Secondary prevention of myocardial infarction--the present state of the ART. Br Med J (1980) 1.16
Intravenous urography in the management of acute retention. Lancet (1977) 1.16